The common shares of Spackman Equities Group trades on the TSX Venture Exchange under the symbol SQG. Visit www.spackmanequities.com for further information.
Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer, expanding treatment options for these patients. DESTINY-Breast06 trial showed Enhertu reduced disease progression ...
Adding nivolumab to neoadjuvant chemotherapy significantly increases pathological complete response rates. (HealthDay News) — For patients with high-risk, early-stage estrogen receptor (ER ...
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer. All patients with breast cancer who may be candidates for antibody-drug ...
In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA ...
The FDA has expanded the label for the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody. This enables the identification of patients with hormone receptor (HR)-positive, HER2-ultralow ...
There is a simple discount patient access scheme for elacestrant. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback